Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

Decorative image.
Date
Aug. 03, 2022
Source
Clinical Info

The Panel updated the following sections of the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the sections are summarized below:

Appendix B: Panel Roster and Financial Disclosures:

  • Updated member conflict of interest information for 2021-2022.
  • Updated roster to include 22 new members, 6 new Section Group Leads and 1 new Leadership member.

Immunizations:

  • The immunizations section has been updated to reflect the recommendation that all people with HIV should receive a COVID-19 vaccine regardless of their CD4 T lymphocyte count or HIV viral load.
  • People with advanced or untreated HIV who received a 2-dose series with one of the mRNA COVID-19 vaccines should receive a third dose of that vaccine at least 28 days after the second dose.
  • The zoster vaccine is now recommended for people with HIV age 18 years old and older in alignment with Advisory Committee on Immunization Practices (ACIP).

For a complete list of updates, please see What's New in the Guidelines. To view or download the guidelines, go to the Adult and Adolescent Opportunistic Infection Guidelines section of Clinical Info’s website. The guideline tables and recommendations can also be downloaded as separate PDF files.

Clinical Info Welcomes Your Feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Please send your comments with the subject line “Adult and Adolescent Opportunistic Infection Guidelines” to HIVinfo@NIH.gov by December 2, 2021.